NEWS HIGHLIGHTS
Published Studies Related to Fosrenol (Lanthanum Carbonate)
Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study. [2011.05]
BACKGROUND: Lanthanum carbonate and sevelamer carbonate are noncalcium phosphate binders used to treat hyperphosphatemia in patients with chronic kidney disease. This is the first study to compare phosphate absorption from a standardized meal ingested with a typical clinical dose of these binders... CONCLUSIONS: In healthy volunteers, 1,000 mg of lanthanum carbonate decreased phosphate absorption by 45% compared with a 21% decrease with 2,400 mg of sevelamer carbonate. Copyright (c) 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. [2011.05]
BACKGROUND: Lanthanum carbonate and sevelamer carbonate are non-calcium-based phosphate binders used to manage hyperphosphataemia in patients with chronic kidney disease (CKD). Patients with CKD may require intravenous or oral active vitamin D. We investigated the effects of lanthanum carbonate and sevelamer carbonate on the bioavailability of oral calcitriol... CONCLUSIONS: Sevelamer carbonate significantly reduces serum concentrations of exogenous calcitriol when administered concomitantly with oral calcitriol, whereas lanthanum carbonate has no significant effect. This should be considered when treating CKD patients who require phosphate binders and oral vitamin D.
Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. [2011.03]
BACKGROUND: Vascular calcification (VC) contributes to cardiovascular disease in haemodialysis (HD) patients. Few controlled studies have addressed interventions to reduce VC but non-calcium-based phosphate binders may be beneficial. No published randomized study to date has assessed the effect of lanthanum carbonate (LC) on VC progression... CONCLUSIONS: Lanthanum carbonate was associated with reduced progression of aortic calcification compared with CC in HD patients over 18 months. (c) 2011 The Authors. Nephrology (c) 2011 Asian Pacific Society of Nephrology.
Efficacy of chewed vs. crushed lanthanum on phosphorus binding in healthy volunteers. [2010.05]
BACKGROUND AND AIM: For effective dietary phosphorous (P) binding, patients are recommended to chew lanthanum tablets completely before swallowing, with or immediately after meals. However, some patients are unable to chew the tablets. It is not known if crushing the tablets prior to taking them with food is as efficacious as chewing them. This study was conducted to compare the efficacy of chewed vs. crushed lanthanum on P binding... CONCLUSION: Both chewed and crushed lanthanum are effective in lowering P absorption after a dietary P load.
Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. [2009.12]
CONCLUSION: In these survival analyses, overall mortality was similar in the lanthanum carbonate and standard therapy groups, but results suggest that there was a survival benefit associated with lanthanum carbonate treatment for patients aged >65 years, who are likely to carry the greatest burden of vascular calcification. These results were similar to those observed in the Dialysis Clinical Outcomes Revisited study, a prospective trial of sevelamer hydrochloride designed to assess survival.
Clinical Trials Related to Fosrenol (Lanthanum Carbonate)
Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5 [Terminated]
The main aim of this research study is to see if giving Fosrenol®, a chewable tablet, to
patients on haemodialysis works as well as other treatments currently used to lower blood
phosphorus levels.
Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan [Recruiting]
This study is a regulatory post marketing surveillance in Japan, and it is a local
prospective and observational study of patients in continuous cyclic peritoneal dialysis
(CCPD) who have received Fosrenol for hyperphosphatemia. The objective of this study is to
assess safety and efficacy of using Fosrenol in clinical practice. This study is also all
case investigation of which the enrollment period is one year, and all patients in CCPD who
received Fosrenol for hyperphosphatemia will be recruited and followed one year.
Fosrenol Post-marketing Surveillance for Hemodialysis in Japan [Recruiting]
This study is a regulatory post marketing surveillance in Japan, and it is a local
prospective and observational study of patients in hemodialysis who received Fosrenol for
hyperphosphatemia. The objective of this study is to assess safety and efficacy of using
Fosrenol in clinical practice. A total 3,000 patients will be recruited and followed 5
years.
The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Chronic Kidney Disease [Recruiting]
The aim of the study is to assess the effects of the drug lanthanum carbonate (a phosphorus
binder drug) on c-terminal and on FGF23 levels in patients with Chronic Kidney Disease
(CKD).
Targeting FGF23 measurement in CKD patients may impact both the progression of kidney
disease and patient mortality.
Fosrenol and Phosphorus Balance - Lanthanum Carbonate [Recruiting]
Positive phosphorus balance and hyperphosphatemia (increased serum phosphorus levels) are
very common complications of people with advanced chronic kidney disease (i. e., stage 5
CKD), including chronic dialysis patients, and are associated with severe morbidity and
increased mortality. Despite attempts to control serum phosphorus with dietary phosphorus
restriction and the use of medicines that bind phosphorus in the gastrointestinal tract so
that the phosphorus cannot be absorbed into the body( also called phosphate binders),
chronic dialysis patients frequently remain hyperphosphatemic, particularly at the time when
they commence each of their regular dialysis treatments.
Fosrenol (lanthanum carbonate, manufactured by Shire Pharmaceuticals) is a gastrointestinal
phosphate binder that appears to have the advantages of being safe, well tolerated and
effective at binding phosphate. There are limited data on the magnitude of binding of
phosphorus by Fosrenol in the human gastrointestinal tract of patients with chronic kidney
disease.
The specific aims for this proposal are as follows:
1. To quantify, under precisely controlled metabolic balance conditions, the increase in
fecal excretion of dietary phosphorus that occurs when patients undergoing chronic
peritoneal dialysis (CPD) ingest Fosrenol (lanthanum carbonate).
2. To examine a dose response relationship between Fosrenol treatment and fecal phosphorus
excretion. The investigators will examine in CPD patients ingesting a constant
phosphorus intake, how much additional phosphorus is excreted in the feces at three
different dose levels of Fosrenol, 1. 5, 3. 0, and 4. 5 g/day.
3. To examine how increased fecal phosphorus losses and more negative phosphorus balance
caused by Fosrenol intake affects serum phosphorus and such hormonal regulators of
phosphorus metabolism as serum parathyroid hormone (PTH), fibroblast growth factor-23,
25-hydroxycholecalciferol (25(OH)D3), 1,25-dihydroxycholecalciferol (1,25(OH)2D3) and
fetuin-A.
4. To assess whether there is any effect of Fosrenol and increased intestinal phosphate
binding on protein-nitrogen balance.
Reports of Suspected Fosrenol (Lanthanum Carbonate) Side Effects
Death (46),
Wrong Technique in Drug Usage Process (24),
Constipation (14),
Intestinal Obstruction (12),
Ileus (11),
Overdose (10),
Large Intestine Perforation (9),
Cardiac Arrest (9),
Myocardial Infarction (8),
Diverticulitis (7), more >>
|
